Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma

PaperCitations, authors & open-access status

Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 64 citations, 2017 year and diamond oa status.

64
Citations
2017
Year
diamond
OA Status

Related on ScholarIQ

Sheng‐Kai Liang
Author
Oncotarget
Journal
Lung Cancer Treatments and Mutations
Topic
Lung Cancer Treatments and Mutations
Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Topic
Gastric Cancer Management and Outcomes
Topic
470M+ articles · free account